T1	Participants 69 103	premenopausal breast cancer trial.
T2	Participants 116 142	Subgroups of breast cancer
T3	Participants 699 738	premenopausal women with breast cancer.
T4	Participants 859 940	500 available tumour specimens from 564 premenopausal patients with breast cancer
T5	Participants 1413 1451	treatment response between the groups.
T6	Participants 1611 1667	tumours with intermediate proliferation defined by Ki-67
T7	Participants 1832 1891	future treatment decisions for patients with breast cancer.
